Figure 3From: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical reviewSwitching TNF inhibitors: ACR response 12 weeks after switching to adalimumab. Data from Bombardieri et al. [25]. ACR, American College of Rheumatology; TNF, tumour necrosis factor.Back to article page